Although the spread of α-synuclein is the strongest correlate of PDD, up to 50% of patients also develop sufficient amyloid-β plaques and tau-containing neurofibrillary tangles for a secondary diagnosis of AD [15]. Here, MAPT is linked to Alzheimer disease.